[go: up one dir, main page]

MA30504B1 - Compositions pharmaceutiques stabilisees comprenant de la fesoterodine - Google Patents

Compositions pharmaceutiques stabilisees comprenant de la fesoterodine

Info

Publication number
MA30504B1
MA30504B1 MA31460A MA31460A MA30504B1 MA 30504 B1 MA30504 B1 MA 30504B1 MA 31460 A MA31460 A MA 31460A MA 31460 A MA31460 A MA 31460A MA 30504 B1 MA30504 B1 MA 30504B1
Authority
MA
Morocco
Prior art keywords
fesoterodine
pharmaceutical compositions
stabilized pharmaceutical
stabilized
isomalt
Prior art date
Application number
MA31460A
Other languages
English (en)
Inventor
Christoph Arth
Hans-Juergen Mika
Michael Komenda
Hans Lindner
Fatima Bicane
Kerstin Paulus
Meike Irngartinger
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30504(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of MA30504B1 publication Critical patent/MA30504B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA FÉSOTÉRODINE OU UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI, AINSI QU'UN STABILISANT SÉLECTIONNÉ PARMI LE GROUPE COMPOSÉ DE XYLITOL, SORBITOL, POLYDEXTROSE, ISOMALT ET DEXTROSE.
MA31460A 2006-06-09 2008-12-08 Compositions pharmaceutiques stabilisees comprenant de la fesoterodine MA30504B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011943 2006-06-09
EP06011941 2006-06-09

Publications (1)

Publication Number Publication Date
MA30504B1 true MA30504B1 (fr) 2009-06-01

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31460A MA30504B1 (fr) 2006-06-09 2008-12-08 Compositions pharmaceutiques stabilisees comprenant de la fesoterodine

Country Status (37)

Country Link
EP (1) EP2029134B1 (fr)
JP (2) JP4743321B2 (fr)
KR (1) KR101316773B1 (fr)
CN (1) CN101466371B (fr)
AP (1) AP2416A (fr)
AR (1) AR061289A1 (fr)
AT (1) ATE517619T1 (fr)
AU (1) AU2007255408B2 (fr)
BR (1) BRPI0712865B1 (fr)
CA (1) CA2652712C (fr)
CR (1) CR10494A (fr)
CU (1) CU23850B1 (fr)
CY (1) CY1111934T1 (fr)
DK (1) DK2029134T3 (fr)
EA (1) EA015909B9 (fr)
EC (1) ECSP089010A (fr)
ES (1) ES2370943T3 (fr)
GT (1) GT200800276A (fr)
HR (1) HRP20110776T1 (fr)
IL (2) IL195732A (fr)
MA (1) MA30504B1 (fr)
MX (1) MX2008015736A (fr)
MY (1) MY146574A (fr)
NI (1) NI200800318A (fr)
NL (1) NL2000690C2 (fr)
NO (1) NO341980B1 (fr)
NZ (1) NZ572616A (fr)
PE (2) PE20120476A1 (fr)
PL (1) PL2029134T3 (fr)
PT (1) PT2029134E (fr)
RS (1) RS51973B (fr)
SI (1) SI2029134T1 (fr)
TN (1) TNSN08505A1 (fr)
TW (2) TWI520735B (fr)
UY (1) UY30394A1 (fr)
WO (1) WO2007141298A1 (fr)
ZA (1) ZA200806411B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122303A2 (fr) * 2008-04-04 2009-10-08 Actavis Group Ptc Ehf Nouveau sel de type mandélate de fésotérodine
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
WO2010130392A1 (fr) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfésotérodine sous forme de sel d'acide tartrique
EP2316432A1 (fr) 2009-10-30 2011-05-04 ratiopharm GmbH Composition contenant de la fésotérodine et des fibres alimentaires
EP2549985A1 (fr) * 2010-03-22 2013-01-30 Cadila Healthcare Limited Compositions pharmaceutiques stables comprenant de la fésotérodine
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508175A1 (fr) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Composition pharmaceutique contenant de la fésotérodine ou un sel ou un solvate de celle-ci
EP2508173A1 (fr) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Composition pharmaceutique stable comportant de la fésotérodine
US20140199401A1 (en) * 2011-07-04 2014-07-17 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
EP2780317A2 (fr) * 2012-05-18 2014-09-24 Alembic Pharmaceuticals Limited Nouveaux marqueurs de référence pour le fumarate de fésotérodine
US20150182629A1 (en) * 2012-07-02 2015-07-02 Hetero Research Foundation Stable compositions of fesoterodine
US10265281B2 (en) 2012-11-02 2019-04-23 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
HRP20210963T1 (hr) * 2013-04-16 2021-09-17 Murray & Poole Enterprises, Ltd. Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (fr) 2017-07-12 2019-01-17 Rontis Hellas S.A. Composition pharmaceutique à libération prolongée contenant de la fésotérodine et procédé de préparation de cette dernière
WO2019132832A1 (fr) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions de comprimés de fumarate de fésotérodine
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
WO2019206391A1 (fr) 2018-04-26 2019-10-31 Rontis Hellas S.A. Composition pharmaceutique à libération prolongée contenant de la fésotérodine et son procédé de préparation
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
IL299544A (en) * 2020-06-30 2023-02-01 Imbria Pharmaceuticals Inc Modified release formulations of modified forms of trimetazidine
WO2023145486A1 (fr) * 2022-01-28 2023-08-03 沢井製薬株式会社 Méthode de production d'une formulation contenant du fumarate de fésotérodine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299277A (zh) * 1998-03-03 2001-06-13 盐野义制药株式会社 含有磷脂酶抑制剂[[3－(2－氨基－1,2－二氧乙基)－2－乙基－1(苯甲基)－1h－吲哚－4－基]氧基]乙酸钠的药用组合物
EP0957073A1 (fr) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
CR10494A (es) 2009-01-19
JP4743321B2 (ja) 2011-08-10
GT200800276A (es) 2009-06-18
EP2029134A1 (fr) 2009-03-04
CA2652712A1 (fr) 2007-12-13
KR101316773B1 (ko) 2013-10-15
MX2008015736A (es) 2009-01-09
TW200814992A (en) 2008-04-01
KR20090026135A (ko) 2009-03-11
IL220800A (en) 2015-03-31
TW201336491A (zh) 2013-09-16
NI200800318A (es) 2011-01-12
PT2029134E (pt) 2011-11-02
JP2009539802A (ja) 2009-11-19
JP4781489B2 (ja) 2011-09-28
HRP20110776T1 (hr) 2011-11-30
EA200802444A1 (ru) 2009-06-30
BRPI0712865B1 (pt) 2021-08-17
AR061289A1 (es) 2008-08-20
PL2029134T3 (pl) 2011-12-30
AP2008004673A0 (en) 2008-12-31
EA015909B9 (ru) 2012-03-30
CN101466371B (zh) 2011-10-05
IL195732A0 (en) 2009-09-01
UY30394A1 (es) 2007-11-30
ZA200806411B (en) 2009-05-27
NZ572616A (en) 2010-11-26
NL2000690A1 (nl) 2007-12-11
DK2029134T3 (da) 2011-10-17
TWI520735B (zh) 2016-02-11
SI2029134T1 (sl) 2012-01-31
CA2652712C (fr) 2014-04-01
PE20120476A1 (es) 2012-04-20
EA015909B1 (ru) 2011-12-30
AU2007255408A1 (en) 2007-12-13
CU23850B1 (es) 2012-10-15
BRPI0712865A2 (pt) 2012-12-18
AP2416A (en) 2012-06-01
CU20080235A7 (es) 2011-04-26
CY1111934T1 (el) 2015-11-04
ECSP089010A (es) 2009-01-30
IL195732A (en) 2013-09-30
ES2370943T3 (es) 2011-12-23
NO20090141L (no) 2009-01-09
PE20080331A1 (es) 2008-06-19
TWI397409B (zh) 2013-06-01
AU2007255408B2 (en) 2013-03-14
MY146574A (en) 2012-08-30
CN101466371A (zh) 2009-06-24
RS51973B (sr) 2012-02-29
ATE517619T1 (de) 2011-08-15
WO2007141298A1 (fr) 2007-12-13
TNSN08505A1 (fr) 2010-04-14
NO341980B1 (no) 2018-03-05
NL2000690C2 (nl) 2008-04-01
EP2029134B1 (fr) 2011-07-27
JP2011140498A (ja) 2011-07-21
HK1128626A1 (en) 2009-11-06

Similar Documents

Publication Publication Date Title
MA30504B1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2007064931A3 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
WO2007002597A3 (fr) Formulations a liberation modifiee d'un sel de bupropion
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
EP2548552A3 (fr) Ensemble de titration pour 1-amino-alkylcyclohexanes
WO2007092065A3 (fr) Composés et compositions servant de modulateurs du lxr
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
WO2007092469A3 (fr) Combinaison de composes organiques
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
UA89315C2 (en) Butylbenzene phthalein intravenous emulsion
MA29969B1 (fr) Formulations de quinolinones
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
WO2008014361A3 (fr) Dérivés cycliques en tant que modulateurs de l'activité des récepteurs de chimiokines
WO2007117605A3 (fr) Nouvelles formulations resistantes aux renversements comprenant des polymeres hydrocolloidaux
WO2005117895A8 (fr) Compositions contenant de la meloxicame
WO2005004915A3 (fr) Compositions contenant meloxicam
WO2005089803A3 (fr) Compositions pharmaceutiques destinees au traitement de maladies de la peau contenant une combinaison d'epinastine et d'un ou plusieurs mineraux ou d'une ou plusieurs matieres premieres
WO2007075923A3 (fr) Traitement de formes de synucleinopathie
WO2009053654A3 (fr) Prodrogues phosphoesters de la gemcitabine comme agents anticancereux